Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Diversified Trust Co

Diversified Trust Co increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 7.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 71,803 shares of the biopharmaceutical company’s stock after buying an additional 5,170 shares during the period. Diversified Trust Co’s holdings in Amicus Therapeutics were worth $712,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics by 5.0% during the 4th quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock valued at $404,308,000 after acquiring an additional 1,360,613 shares during the period. Perceptive Advisors LLC raised its holdings in Amicus Therapeutics by 1.3% during the fourth quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock worth $398,135,000 after purchasing an additional 364,539 shares during the last quarter. Wellington Management Group LLP grew its holdings in Amicus Therapeutics by 101.9% in the fourth quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after purchasing an additional 7,666,335 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after purchasing an additional 2,307,385 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Amicus Therapeutics in the fourth quarter valued at $35,915,000.

Wall Street Analysts Forecast Growth

Several research firms recently commented on FOLD. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective on the stock. Bank of America lowered their price target on shares of Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Guggenheim upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, May 14th. Morgan Stanley lowered their target price on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, May 10th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $10.34, for a total value of $77,550.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,168,002.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $10.34, for a total transaction of $77,550.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The disclosure for this sale can be found here. 2.20% of the stock is owned by insiders.

Amicus Therapeutics Trading Down 1.2 %

FOLD traded down $0.14 during trading on Wednesday, hitting $11.58. The company’s stock had a trading volume of 254,873 shares, compared to its average volume of 2,854,833. The firm’s 50 day moving average price is $10.27 and its 200-day moving average price is $11.05. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57. The stock has a market cap of $3.43 billion, a PE ratio of -23.92 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.03 and a quick ratio of 2.61.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The company’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.15) EPS. On average, analysts expect that Amicus Therapeutics, Inc. will post -0.12 earnings per share for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.